Abstract
Primary PCI is an effective reperfusion strategy for acute MI patients, which has evolved significantly in the last decade. While many adjunctive therapies have contributed to its success, substantial obstacles remain before optimal reperfusion can be achieved. Anti-platelet therapy with aspirin, clopidogrel and GP IIb / IIIa inhibitors reduces early ischemic complications, improves microvascular function and, potentially, affects the inflammatory response to ischemic injury. Current anti-thrombin therapy with UFH can be improved with LMWH, and, possibly with direct thrombin inhibitors. A number of important aspects of this strategy, though, need still to be elucidated. We need to optimize microvascular protection before and during PCI in order to capitalize on the myocardial sparing effects of reperfusion therapy. This will be probably achieved with a combination of pharmacological interventions and mechanical emboli protection devices. Improved and more targeted anti-inflammatory therapy should decrease the effects of neutrophil-related reperfusion injury, while a variety of metabolic interventions might preserve myocardial function during ischemia and after reperfusion.
Keywords: Acute Myocardia, Revascularization, Anti-platelet therapy, ischemia
Current Pharmaceutical Design
Title: Adjunctive Therapy for Percutaneous Revascularization in Acute Myocardial Infarction
Volume: 10 Issue: 4
Author(s): Sorin J. Brener and Eric J. Topol
Affiliation:
Keywords: Acute Myocardia, Revascularization, Anti-platelet therapy, ischemia
Abstract: Primary PCI is an effective reperfusion strategy for acute MI patients, which has evolved significantly in the last decade. While many adjunctive therapies have contributed to its success, substantial obstacles remain before optimal reperfusion can be achieved. Anti-platelet therapy with aspirin, clopidogrel and GP IIb / IIIa inhibitors reduces early ischemic complications, improves microvascular function and, potentially, affects the inflammatory response to ischemic injury. Current anti-thrombin therapy with UFH can be improved with LMWH, and, possibly with direct thrombin inhibitors. A number of important aspects of this strategy, though, need still to be elucidated. We need to optimize microvascular protection before and during PCI in order to capitalize on the myocardial sparing effects of reperfusion therapy. This will be probably achieved with a combination of pharmacological interventions and mechanical emboli protection devices. Improved and more targeted anti-inflammatory therapy should decrease the effects of neutrophil-related reperfusion injury, while a variety of metabolic interventions might preserve myocardial function during ischemia and after reperfusion.
Export Options
About this article
Cite this article as:
Brener J. Sorin and Topol J. Eric, Adjunctive Therapy for Percutaneous Revascularization in Acute Myocardial Infarction, Current Pharmaceutical Design 2004; 10 (4) . https://dx.doi.org/10.2174/1381612043453333
DOI https://dx.doi.org/10.2174/1381612043453333 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Factors Affecting 30-Day Mortality in Chinese Patients with Acute Myocardial Infarction: A Registry-Based Cohort Study
Vascular Disease Prevention (Discontinued) Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Cardioprotective Effects of Sour Cherry Seed Extract (SCSE) on the Hypercholesterolemic Rabbit Heart
Current Pharmaceutical Design Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport
Mini-Reviews in Medicinal Chemistry Role of Dietary Polyphenols in Attenuating Brain Edema and Cell Swelling in Cerebral Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Adverse Effects of Cigarette Smoke and Induction of Oxidative Stress in Cardiomyocytes and Vascular Endothelium
Current Pharmaceutical Design Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science The Role of Platelets and their Microparticles in Rehabilitation of Ischemic Brain Tissue
CNS & Neurological Disorders - Drug Targets Cardiovascular Effects of the Phytoestrogen Genistein
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Myocardial Reperfusion Injury
Current Vascular Pharmacology Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design Targeting the p53 Pathway of Apoptosis
Current Pharmaceutical Design Caspase-1-independent Maturation of IL-1β in Ischemic Brain Injury: is there a Role for Gelatinases?
Mini-Reviews in Medicinal Chemistry Guiding Lineage Specific Differentiation of SHED for Target Tissue/Organ Regeneration
Current Stem Cell Research & Therapy Application of Mitochondria-Targeted Pharmaceuticals for the Treatment of Heart Disease
Current Pharmaceutical Design Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity
Current Neuropharmacology